Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercell, a developer of vaccines for the prevention and treatment of infectious diseases, has named Thomas Lingelbach as the new CEO, effective 10 May 2011.
Subscribe to our email newsletter
Lingelbach has succeeded Gerd Zettlmeissl, who is resigning from the company to pursue other personal and professional interests.
Lingelbach has held leading positions of increasing international responsibility at Hoechst, Chiron Vaccines and Novartis Vaccines and Diagnostics, before joining Intercell in 2006 as chief operating officer.
At Intercell, Lingelbach has been inter alia chiefly responsible for the manufacturing and March 2009 licensure in the US and Europe of the company’s first product, a vaccine to prevent Japanese Encephalitis.
Lingelbach said he will be delighted to work as the new CEO with the experienced Management Board of Intercell, Staph Bakali, who joined the Management Board last year as chief business officer and chief financial officer Reinhard Kandera.